Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Rating of “Hold” by Brokerages

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned an average recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $9.8333.

AYTU has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Ascendiant Capital Markets raised their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Finally, Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Daytona Street Capital LLC purchased a new position in shares of Aytu BioPharma during the 4th quarter worth approximately $26,000. Rothschild Wealth LLC purchased a new position in shares of Aytu BioPharma during the 4th quarter worth approximately $52,000. Bellevue Asset Management LLC purchased a new position in shares of Aytu BioPharma during the 4th quarter worth approximately $65,000. XTX Topco Ltd purchased a new position in shares of Aytu BioPharma during the 4th quarter worth approximately $67,000. Finally, DRW Securities LLC purchased a new position in shares of Aytu BioPharma during the 4th quarter worth approximately $76,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Stock Performance

Shares of Aytu BioPharma stock opened at $2.31 on Friday. Aytu BioPharma has a 12-month low of $1.65 and a 12-month high of $3.07. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The stock has a market cap of $24.79 million, a PE ratio of -0.50 and a beta of 0.24. The company has a 50-day moving average of $2.34 and a two-hundred day moving average of $2.46.

Aytu BioPharma (NASDAQ:AYTU) last issued its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The company had revenue of $12.41 million during the quarter, compared to analysts’ expectations of $12.05 million. On average, research analysts anticipate that Aytu BioPharma will post -0.73 EPS for the current fiscal year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.